BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology 2015;149:1275-1285.e2. [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003] [Cited by in Crossref: 205] [Cited by in F6Publishing: 213] [Article Influence: 25.6] [Reference Citation Analysis]
Number Citing Articles
1 Vitali R, Palone F, Armuzzi A, Fulci V, Negroni A, Carissimi C, Cucchiara S, Stronati L. Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease. J Crohns Colitis 2023;17:92-102. [PMID: 36040453 DOI: 10.1093/ecco-jcc/jjac110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hu T, Ren L, Li H, An Z. Effects of Vitamin D supplementation or deficiency on metabolic phenotypes in mice of different sexes. J Steroid Biochem Mol Biol 2023;229:106250. [PMID: 36708934 DOI: 10.1016/j.jsbmb.2023.106250] [Reference Citation Analysis]
3 Liu XY, Tang H, Zhou QY, Zeng YL, Chen D, Xu H, Li Y, Tan B, Qian JM. Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology. World J Gastroenterol 2023; 29(2): 272-285 [PMID: 36687128 DOI: 10.3748/wjg.v29.i2.272] [Reference Citation Analysis]
4 Ramos L, Teo-Loy J, Barreiro-de Acosta M. Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. Front Med (Lausanne) 2022;9:1102420. [PMID: 36698823 DOI: 10.3389/fmed.2022.1102420] [Reference Citation Analysis]
5 Ludwig EK, Hobbs KJ, McKinney-Aguirre CA, Gonzalez LM. Biomarkers of Intestinal Injury in Colic. Animals (Basel) 2023;13. [PMID: 36670767 DOI: 10.3390/ani13020227] [Reference Citation Analysis]
6 Calderon-Gonzalez R, Lee A, Lopez-Campos G, Hancock SJ, Sa-Pessoa J, Dumigan A, McMullan R, Campbell EL, Bengoechea JA. Modelling the Gastrointestinal Carriage of Klebsiella pneumoniae Infections. mBio 2023;:e0312122. [PMID: 36598189 DOI: 10.1128/mbio.03121-22] [Reference Citation Analysis]
7 Cecerska-Heryć E, Ronkowski B, Heryć R, Serwin N, Grygorcewicz B, Roszak M, Galant K, Dołęgowska B. Proteomic and lipidomic biomarkers in the diagnosis and progression of inflammatory bowel disease - a review. Proteomics Clin Appl 2023;17:e2200003. [PMID: 36043901 DOI: 10.1002/prca.202200003] [Reference Citation Analysis]
8 Ali KA, Maity A, Roy SD, Das Pramanik S, Pratim Das P, Shaharyar MA. Insight into the mechanism of steroidal and non-steroidal anti-inflammatory drugs. How Synthetic Drugs Work 2023. [DOI: 10.1016/b978-0-323-99855-0.00004-x] [Reference Citation Analysis]
9 Anand S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, Anwar Khan A, Elderdery AY. Resolvins Lipid Mediators: Potential Therapeutic Targets in Alzheimer and Parkinson Disease. Neuroscience 2022;507:139-48. [PMID: 36372297 DOI: 10.1016/j.neuroscience.2022.11.001] [Reference Citation Analysis]
10 Ibrahim I, Syamala S, Ayariga JA, Xu J, Robertson BK, Meenakshisundaram S, Ajayi OS. Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids. Metabolites 2022;12. [PMID: 36557285 DOI: 10.3390/metabo12121247] [Reference Citation Analysis]
11 Liu Y, Kong X, You Y, Xiang L, Zhang Y, Wu R, Zhou L, Duan L. S100A8-Mediated NLRP3 Inflammasome-Dependent Pyroptosis in Macrophages Facilitates Liver Fibrosis Progression. Cells 2022;11. [PMID: 36429008 DOI: 10.3390/cells11223579] [Reference Citation Analysis]
12 Younis NAM, Gomaa AA, Ibrahim AH, Abdelkader MS, Desoukey SY. The genus Agapanthus: A review on traditional uses, pharmacological and phytochemical attributes. South African Journal of Botany 2022;150:1168-83. [DOI: 10.1016/j.sajb.2022.09.029] [Reference Citation Analysis]
13 Murphy ME, Bhattacharya S, Axelrad JE. Diagnosis and Monitoring of Ulcerative Colitis. Clin Colon Rectal Surg 2022;35:421-7. [PMID: 36591402 DOI: 10.1055/s-0042-1758047] [Reference Citation Analysis]
14 Wu J, Luo Y, Shen Y, Hu Y, Zhu F, Wu J, Liu Y. Integrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis. Drug Des Devel Ther 2022;16:3739-76. [PMID: 36324421 DOI: 10.2147/DDDT.S375281] [Reference Citation Analysis]
15 Wang S, Miao S, Qiu X, Wu J, Wang Y. Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn's disease. Medicine (Baltimore) 2022;101:e31163. [PMID: 36281159 DOI: 10.1097/MD.0000000000031163] [Reference Citation Analysis]
16 Spencer EA, Agrawal M, Jess T. Prognostication in inflammatory bowel disease. Front Med (Lausanne) 2022;9:1025375. [PMID: 36275829 DOI: 10.3389/fmed.2022.1025375] [Reference Citation Analysis]
17 Calderon-gonzalez R, Lee A, Lopez-campos G, Hancock SJ, Sa-pessoa J, Dumigan A, Mcmullan R, Campbell EL, Bengoechea JA. Modelling the gastrointestinal carriage of Klebsiella pneumoniae infections.. [DOI: 10.1101/2022.10.03.510744] [Reference Citation Analysis]
18 Romero-mascarell C, Fernández-esparrach G, Rodríguez-de Miguel C, Masamunt MC, Rodríguez S, Rimola J, Urpí M, Casanova GS, Ordás I, Ricart E, Caballol B, Fernández-clotet A, Panés J, Llach J, González-suárez B. Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue? Diagnostics 2022;12:2226. [DOI: 10.3390/diagnostics12092226] [Reference Citation Analysis]
19 Liu C, Yu R, Zhang J, Wei S, Xue F, Guo Y, He P, Shang L, Dong W. Research hotspot and trend analysis in the diagnosis of inflammatory bowel disease: A machine learning bibliometric analysis from 2012 to 2021. Front Immunol 2022;13:972079. [DOI: 10.3389/fimmu.2022.972079] [Reference Citation Analysis]
20 Wu RY, Xiao K, Hotte N, Tandon P, Elloumi Y, Ambrosio L, Dunsmore G, Elahi S, Kroeker KI, Dieleman LA, Madsen KL, Huang V. Elevated IL-6 and IL-22 in Early Pregnancy Are Associated with Worse Disease Course in Women with Inflammatory Bowel Disease. IJMS 2022;23:10281. [DOI: 10.3390/ijms231810281] [Reference Citation Analysis]
21 Abe I, Shiga H, Chiba H, Miyazawa T, Oomori S, Shimoyama Y, Moroi R, Kuroha M, Kakuta Y, Kinouchi Y, Masamune A. Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease. J Gastroenterol Hepatol 2022;37:1741-8. [PMID: 35641439 DOI: 10.1111/jgh.15907] [Reference Citation Analysis]
22 Bhandari A, Basnet BK. Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report. JNMA J Nepal Med Assoc 2022;60:825-7. [PMID: 36705134 DOI: 10.31729/jnma.7590] [Reference Citation Analysis]
23 Loktionov A. Colon mucus in colorectal neoplasia and beyond. World J Gastroenterol 2022; 28(32): 4475-4492 [DOI: 10.3748/wjg.v28.i32.4475] [Reference Citation Analysis]
24 Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac170. [PMID: 35917172 DOI: 10.1093/ibd/izac170] [Reference Citation Analysis]
25 Song Z, Zhang M, Ren Y, Iang B. [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis]. Nan Fang Yi Ke Da Xue Xue Bao 2022;42:997-1005. [PMID: 35869761 DOI: 10.12122/j.issn.1673-4254.2022.07.05] [Reference Citation Analysis]
26 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
27 Huang X, Li Y, Zhuang P, Liu X, Zhang Y, Zhang P, Jiao J. Habitual Fish Oil Supplementation and Risk of Incident Inflammatory Bowel Diseases: A Prospective Population-Based Study. Front Nutr 2022;9:905162. [DOI: 10.3389/fnut.2022.905162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Alghoul Z, Yang C, Merlin D. The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. Biomedicines 2022;10:1492. [PMID: 35884797 DOI: 10.3390/biomedicines10071492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhou Z, Zhang Y, Pan Y, Yang X, Li L, Gao C, He C. A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis. Front Med (Lausanne) 2022;9:872831. [PMID: 35572985 DOI: 10.3389/fmed.2022.872831] [Reference Citation Analysis]
30 Roda J, Maia C, Almeida S, Oliveira RC, Ferreira R, Oliveira G. Faecal calprotectin and rectal histological inflammatory markers in cystic fibrosis: a single-centre study. bmjpo 2022;6:e001422. [DOI: 10.1136/bmjpo-2022-001422] [Reference Citation Analysis]
31 Dash S, Syed YA, Khan MR. Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders. Front Cell Dev Biol 2022;10:880544. [DOI: 10.3389/fcell.2022.880544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Wu H, Hu T, Zhang L, Xia X, Liu X, Zhu Q, Wang M, Sun Z, Hao H, Cui Y, Parrish AR, Li D, Hill MA, Xu C, Liu Z. Abdominal Aortic Endothelial Dysfunction Occurs in Female Mice With Dextran Sodium Sulfate-Induced Chronic Colitis Independently of Reactive Oxygen Species Formation. Front Cardiovasc Med 2022;9:871335. [DOI: 10.3389/fcvm.2022.871335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhang YL, Chen Q, Zheng L, Zhang ZW, Chen YJ, Dai YC, Tang ZP. Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss. World J Gastroenterol 2022; 28(13): 1315-1328 [DOI: 10.3748/wjg.v28.i13.1315] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Chey SW, Westerhoff M, Chey WD. Transient Lymphocytic Colitis After SARS-CoV2 mRNA Vaccine. Am J Gastroenterol 2022;117:685-7. [PMID: 35130188 DOI: 10.14309/ajg.0000000000001673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Yan W, Meihao W, Zihan S, Lingjie H, Haotian C, Qian C, Lianli S. Correlation Between Crohn Disease Activity and Serum Selenium Concentration. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.03.005] [Reference Citation Analysis]
36 Kikut J, Mokrzycka M, Drozd A, Grzybowska-chlebowczyk U, Ziętek M, Szczuko M. Involvement of Proinflammatory Arachidonic Acid (ARA) Derivatives in Crohn’s Disease (CD) and Ulcerative Colitis (UC). JCM 2022;11:1861. [DOI: 10.3390/jcm11071861] [Reference Citation Analysis]
37 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
38 Zhou Z, Zhang Y, Yang X, Pan Y, Li L, Gao C, He C. Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease. Front Immunol 2022;13:865968. [DOI: 10.3389/fimmu.2022.865968] [Reference Citation Analysis]
39 Wang Y, Li C, Wang W, Wang J, Li J, Qian S, Cai C, Liu Y. Serum Albumin to Globulin Ratio is Associated with the Presence and Severity of Inflammatory Bowel Disease. JIR 2022;Volume 15:1907-20. [DOI: 10.2147/jir.s347161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ticona LA, Sánchez ÁR, Bastante MH, Serban AM, Hernáiz MJ. Anti-inflammatory properties of Neowerdermannia vorwerkii Frič ‘Achacana’ used in treating stomach-related ailments. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115198] [Reference Citation Analysis]
41 Park SB, Kim S, Lee J, Lee YJ, Baek DH, Seo GS, Kim ES, Kim S, Kim SY. Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02178-0] [Reference Citation Analysis]
42 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Keenan JI, Frizelle FA. Biomarkers to Detect Early-Stage Colorectal Cancer. Biomedicines 2022;10:255. [PMID: 35203465 DOI: 10.3390/biomedicines10020255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Qiu H, Weng Q. Screening of Crucial Differentially-Methylated/Expressed Genes for Alzheimer's Disease. Am J Alzheimers Dis Other Demen 2022;37:15333175221116220. [PMID: 35848539 DOI: 10.1177/15333175221116220] [Reference Citation Analysis]
45 Jacobsen GE, Fernández I, Quintero MA, Santander AM, Pignac-kobinger J, Damas OM, Deshpande AR, Kerman DH, Ban Y, Gao Z, Silva TC, Wang L, Beecham AH, Mccauley JL, Burgueño JF, Abreu MT. Lamina Propria Phagocyte Profiling Reveals Targetable Signaling Pathways in Refractory Inflammatory Bowel Disease. Gastro Hep Advances 2022;1:380-392. [DOI: 10.1016/j.gastha.2022.01.005] [Reference Citation Analysis]
46 Yadav M, Bhambi M. Microbiome Based Diseases Diagnostics. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00012-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Chen R, Zheng J, Li L, Li C, Chao K, Zeng Z, Chen M, Zhang S. Metabolomics facilitate the personalized management in inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211064489. [PMID: 34987610 DOI: 10.1177/17562848211064489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Wang R, Zheng L, Xu Q, Xu L, Wang D, Li J, Lu G, Huang C, Wang Y. Unveiling the structural properties of water-soluble lignin from gramineous biomass by autohydrolysis and its functionality as a bioactivator (anti-inflammatory and antioxidative). Int J Biol Macromol 2021;191:1087-95. [PMID: 34600953 DOI: 10.1016/j.ijbiomac.2021.09.124] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
50 Mitselos IV, Fousekis FS, Lamouri C, Katsanos KH, Christodoulou DK. Current noninvasive modalities in Crohn's disease monitoring. Ann Gastroenterol 2021;34:770-80. [PMID: 34815642 DOI: 10.20524/aog.2021.0648] [Reference Citation Analysis]
51 Li B, Wu Y, Wang Z, Xing M, Xu W, Zhu Y, Du P, Wang X, Yang H. Non-invasive diagnosis of Crohn's disease based on SERS combined with PCA-SVM. Anal Methods 2021;13:5264-73. [PMID: 34665186 DOI: 10.1039/d1ay01377g] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Shao J, Li Z, Gao Y, Zhao K, Lin M, Li Y, Wang S, Liu Y, Chen L. Construction of a "Bacteria-Metabolites" Co-Expression Network to Clarify the Anti-Ulcerative Colitis Effect of Flavonoids of Sophora flavescens Aiton by Regulating the "Host-Microbe" Interaction. Front Pharmacol 2021;12:710052. [PMID: 34721011 DOI: 10.3389/fphar.2021.710052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
53 Corsi F, Sorrentino L, Albasini S, Colombo F, Cigognini M, Massari A, Morasso C, Mazzucchelli S, Piccotti F, Ardizzone S, Sampietro GM, Truffi M. Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725726. [PMID: 34621763 DOI: 10.3389/fmed.2021.725726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Sherlock ME, Zachos M, Issenman RM, Mulder DJ. Clinical and Laboratory Characteristics Are Associated With Biologic Therapy Use in Pediatric Inflammatory Bowel Disease: A Retrospective Cohort Study. J Can Assoc Gastroenterol 2021;4:e92-e100. [PMID: 34617006 DOI: 10.1093/jcag/gwaa033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut 2021;70:1978-88. [PMID: 34145045 DOI: 10.1136/gutjnl-2021-324855] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 24.5] [Reference Citation Analysis]
56 Lundgren D, Widbom L, Hultdin J, Karling P. Preclinical Markers in Inflammatory Bowel Disease. A Nested Case–Control Study. Crohn's & Colitis 360 2021;3:otab072. [DOI: 10.1093/crocol/otab072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Li Y, Sun Y, Zhang X, Wang X, Yang P, Guan X, Wang Y, Zhou X, Hu P, Jiang T, Xu Z. Relationship between amniotic fluid metabolic profile with fetal gender, maternal age, and gestational week. BMC Pregnancy Childbirth 2021;21:638. [PMID: 34537001 DOI: 10.1186/s12884-021-04116-6] [Reference Citation Analysis]
58 Raffals LE, Saha S, Bewtra M, Norris C, Dobes A, Heller C, O'Charoen S, Fehlmann T, Sweeney S, Weaver A, Bishu S, Cross R, Dassopoulos T, Fischer M, Yarur A, Hudesman D, Parakkal D, Duerr R, Caldera F, Korzenik J, Pekow J, Wells K, Bohm M, Perera L, Kaur M, Ciorba M, Snapper S, Scoville EA, Dalal S, Wong U, Lewis JD. The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). Inflamm Bowel Dis 2022;28:192-9. [PMID: 34436563 DOI: 10.1093/ibd/izab071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Basso D, Padoan A, D'Incà R, Arrigoni G, Scapellato ML, Contran N, Franchin C, Lorenzon G, Mescoli C, Moz S, Bozzato D, Rugge M, Plebani M. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis. Clin Chem Lab Med 2020;58:968-79. [PMID: 32229654 DOI: 10.1515/cclm-2019-1125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Nakayasu ES, Gritsenko M, Piehowski PD, Gao Y, Orton DJ, Schepmoes AA, Fillmore TL, Frohnert BI, Rewers M, Krischer JP, Ansong C, Suchy-Dicey AM, Evans-Molina C, Qian WJ, Webb-Robertson BM, Metz TO. Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nat Protoc 2021;16:3737-60. [PMID: 34244696 DOI: 10.1038/s41596-021-00566-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
61 Wang Z, Verstockt B, Sabino J, Vermeire S, Ferrante M, Declerck P, Dreesen E. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. Br J Clin Pharmacol 2021. [PMID: 34197653 DOI: 10.1111/bcp.14971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Zhou J, Yang Y, Wang YL, Zhao Y, Ye WJ, Deng SY, Lang JY, Lu S. Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease. World J Gastroenterol 2021; 27(22): 3073-3084 [PMID: 34168409 DOI: 10.3748/wjg.v27.i22.3073] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Crispino F, Grova M, Maida M, Renna S, Mocciaro F, Casà A, Rizzuto G, Tesè L, Scimeca D, Di Mitri R, Macaluso FS, Orlando A. Blood-based prognostic biomarkers in Crohn's Disease patients on biologics: a promising tool to predict endoscopic outcomes. Expert Opin Biol Ther 2021;21:1133-41. [PMID: 34042009 DOI: 10.1080/14712598.2021.1935857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, Gasbarrini A, Franceschi F. Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:6242. [PMID: 34200555 DOI: 10.3390/ijms22126242] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 20.0] [Reference Citation Analysis]
65 Barani M, Rahdar A, Sargazi S, Amiri MS, Sharma PK, Bhalla N. Nanotechnology for inflammatory bowel disease management: Detection, imaging and treatment. Sensing and Bio-Sensing Research 2021;32:100417. [DOI: 10.1016/j.sbsr.2021.100417] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
66 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
67 Zhao C, Huang H, Pan Q, Huang W, Peng W, Xu H, Feng Z, Du Y, Nie Y, Zhou Y. Unconjugated Bilirubin Attenuates DSS-Induced Colitis Potentially via Enhancement of Bilirubin Reabsorption. Front Pharmacol 2021;12:654808. [PMID: 34093187 DOI: 10.3389/fphar.2021.654808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Khalid HN, Abd El Gayed EM, Elrsool AMA, Bazid HAS. Evaluation of serum and urinary orsomucoid protein A in psoriatic patients and their relation to severity of disease. J Cosmet Dermatol 2021. [PMID: 33905172 DOI: 10.1111/jocd.14182] [Reference Citation Analysis]
69 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 402] [Cited by in F6Publishing: 391] [Article Influence: 201.0] [Reference Citation Analysis]
70 Burisch J, Zhang H, Choong CK, Nelson D, Naegeli A, Gibble T, Goetz I, Egeberg A. Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211004841. [PMID: 33868458 DOI: 10.1177/17562848211004841] [Reference Citation Analysis]
71 Sun Y, Qin H, Zhang H, Feng X, Yang L, Hou DX, Chen J. Fisetin inhibits inflammation and induces autophagy by mediating PI3K/AKT/mTOR signaling in LPS-induced RAW264.7 cells. Food Nutr Res 2021;65. [PMID: 33841067 DOI: 10.29219/fnr.v65.6355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
72 Harris C, Harris RJ, Downey L, Gwiggner M. Management of Crohn's disease in an immunosuppressed COVID-19-positive patient: safety-driven prioritisation of nutritional therapy as a bridge to restarting immunosuppression. BMJ Case Rep 2021;14:e239404. [PMID: 33753379 DOI: 10.1136/bcr-2020-239404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
74 Constant BD, Khushal S, Jiang J, Bost JE, Chaisson E, Conklin LS. Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr 2021;72:410-6. [PMID: 33439565 DOI: 10.1097/MPG.0000000000002975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Farsi F, Ebrahimi-Daryani N, Golab F, Akbari A, Janani L, Karimi MY, Irandoost P, Alamdari NM, Agah S, Vafa M. A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis. Eur J Nutr 2021;60:3397-410. [PMID: 33620550 DOI: 10.1007/s00394-021-02514-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
76 Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, Mori A, Fukunaga S, Araki T, Morita M, Tsuruta K, Yamasaki H, Torimura T. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease. Mediators Inflamm 2021;2021:8825374. [PMID: 33623482 DOI: 10.1155/2021/8825374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
77 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MDLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterología y Hepatología (English Edition) 2021;44:87-95. [DOI: 10.1016/j.gastre.2020.04.010] [Reference Citation Analysis]
78 Zhang MH, Wang H, Wang HG, Wen X, Yang XZ. Effective immune-inflammation index for ulcerative colitis and activity assessments. World J Clin Cases 2021; 9(2): 334-343 [PMID: 33521101 DOI: 10.12998/wjcc.v9.i2.334] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
79 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
80 Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol 2021;56:560-9. [PMID: 33942166 DOI: 10.1007/s00535-021-01793-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
81 McNerney MP, Doiron KE, Ng TL, Chang TZ, Silver PA. Theranostic cells: emerging clinical applications of synthetic biology. Nat Rev Genet 2021;22:730-46. [PMID: 34234299 DOI: 10.1038/s41576-021-00383-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
82 Sultan K, Becher N. Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_3] [Reference Citation Analysis]
83 Levi-Galibov O, Lavon H, Wassermann-Dozorets R, Pevsner-Fischer M, Mayer S, Wershof E, Stein Y, Brown LE, Zhang W, Friedman G, Nevo R, Golani O, Katz LH, Yaeger R, Laish I, Porco JA, Sahai E, Shouval DS, Kelsen D, Scherz-Shouval R. Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. Nat Commun 2020;11:6245. [PMID: 33288768 DOI: 10.1038/s41467-020-20054-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
84 Livshits G, Kalinkovich A. Receptors for pro-resolving mediators as a therapeutic tool for smooth muscle remodeling-associated disorders. Pharmacol Res 2021;164:105340. [PMID: 33276103 DOI: 10.1016/j.phrs.2020.105340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
85 Scuderi SA, Casili G, Lanza M, Filippone A, Paterniti I, Esposito E, Campolo M. Modulation of NLRP3 Inflammasome Attenuated Inflammatory Response Associated to Diarrhea-Predominant Irritable Bowel Syndrome. Biomedicines 2020;8:E519. [PMID: 33233503 DOI: 10.3390/biomedicines8110519] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
86 Gunji N, Katakura K, Abe K, Kawashima K, Fujiwara T, Onizawa M, Takahashi A, Ohira H. Upregulation of complement C1q reflects mucosal regeneration in a mouse model of colitis. Med Mol Morphol 2021;54:87-94. [PMID: 33029672 DOI: 10.1007/s00795-020-00266-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Dragoni G, Innocenti T, Galli A. Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? Dig Dis 2021;39:190-203. [PMID: 32942275 DOI: 10.1159/000511641] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
88 Ishida N, Miyazu T, Matsuura T, Takano R, Tamura S, Kagami T, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. Int J Colorectal Dis 2020;35:1729-39. [PMID: 32472230 DOI: 10.1007/s00384-020-03636-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
89 Hayford FEA, Dolman RC, Blaauw R, Nienaber A, Smuts CM, Malan L, Ricci C. The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis. Respir Res 2020;21:223. [PMID: 32847532 DOI: 10.1186/s12931-020-01488-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
90 Shinde T, Vemuri R, Shastri S, Perera AP, Gondalia SV, Beale DJ, Karpe AV, Eri R, Stanley R. Modulating the Microbiome and Immune Responses Using Whole Plant Fibre in Synbiotic Combination with Fibre-Digesting Probiotic Attenuates Chronic Colonic Inflammation in Spontaneous Colitic Mice Model of IBD. Nutrients 2020;12:E2380. [PMID: 32784883 DOI: 10.3390/nu12082380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
91 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
92 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
94 Dreesen E, Berends S, Laharie D, D'Haens G, Vermeire S, Gils A, Mathôt R. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. Br J Clin Pharmacol 2021;87:106-18. [PMID: 32415677 DOI: 10.1111/bcp.14364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
95 Mavropoulou E, Mechie NC, Knoop R, Petzold G, Ellenrieder V, Kunsch S, Pilavakis Y, Amanzada A. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. PLoS One. 2020;15:e0233811. [PMID: 32470973 DOI: 10.1371/journal.pone.0233811] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
96 Jerkic SP, Michel F, Donath H, Herrmann E, Schubert R, Rosewich M, Zielen S. Calprotectin as a New Sensitive Marker of Neutrophilic Inflammation in Patients with Bronchiolitis Obliterans. Mediators Inflamm 2020;2020:4641585. [PMID: 32410855 DOI: 10.1155/2020/4641585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
97 Ishida N, Miyazu T, Takano R, Tamura S, Tani S, Kagami T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Miyajima H, Sugimoto K. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterol 2020;20:114. [PMID: 32306914 DOI: 10.1186/s12876-020-01256-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
98 Brennan Laing B, Cavadino A, Ellett S, Ferguson LR. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations. Nutrients 2020;12:E1139. [PMID: 32325778 DOI: 10.3390/nu12041139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
99 Tian X, Gao J, Liu M, Lei Y, Wang F, Chen J, Chu P, Gao J, Long F, Liang M, Long X, Chu H, Liu C, Li X, Sun Q, Li G, Yang Y. Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery. J Med Chem 2020;63:3881-95. [PMID: 32223194 DOI: 10.1021/acs.jmedchem.9b01663] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
100 González-Moret R, Cebolla A, Cortés X, Baños RM, Navarrete J, de la Rubia JE, Lisón JF, Soria JM. The effect of a mindfulness-based therapy on different biomarkers among patients with inflammatory bowel disease: a randomised controlled trial. Sci Rep 2020;10:6071. [PMID: 32269278 DOI: 10.1038/s41598-020-63168-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
101 Hadian Y, Fregoso D, Nguyen C, Bagood MD, Dahle SE, Gareau MG, Isseroff RR. Microbiome-skin-brain axis: A novel paradigm for cutaneous wounds. Wound Repair Regen 2020;28:282-92. [PMID: 32034844 DOI: 10.1111/wrr.12800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
102 Piotrowicz G, Klufczyńska A, Banaszkiewicz P, Dorosz Ł, Rydzewska G. Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease. Prz Gastroenterol 2021;16:15-22. [PMID: 33986883 DOI: 10.5114/pg.2020.93539] [Reference Citation Analysis]
103 Zhang J, Xu M, Zhou W, Li D, Zhang H, Chen Y, Ning L, Zhang Y, Li S, Yu M, Chen Y, Zeng H, Cen L, Zhou T, Zhou X, Lu C, Yu C, Li Y, Sun J, Kong X, Shen Z. Deficiency in the anti-apoptotic protein DJ-1 promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via p53. J Biol Chem 2020;295:4237-51. [PMID: 32075910 DOI: 10.1074/jbc.RA119.010143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
104 Arafah K, Kriegsmann M, Renner M, Lasitschka F, Fresnais M, Kriegsmann K, von Winterfeld M, Goeppert B, Kriegsmann J, Casadonte R, Kazdal D, Bulet P, Longuespée R. Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease. Proteomics Clin Appl 2020;14:e1900110. [PMID: 32003543 DOI: 10.1002/prca.201900110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
105 Wohnhaas CT, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K, Strobel B, Eisele C, Wiech F, Jakob I, Gantner F, Herichova I, Vinisko R, Böcher WO, Visvanathan S, Shen F, Panzenbeck M, Raymond E, Reber SO, Delić D, Baum P. Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohns Colitis 360 2020;2:otaa003. [PMID: 32551441 DOI: 10.1093/crocol/otaa003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
106 Cornish JS, Wirthgen E, Däbritz J. Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease.Front Med (Lausanne). 2020;7:8. [PMID: 32064265 DOI: 10.3389/fmed.2020.00008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
107 Oosterloo BC, Van't Land B, de Jager W, Rutten NB, Klöpping M, Garssen J, Vlieger AM, van Elburg RM. Neonatal Antibiotic Treatment Is Associated With an Altered Circulating Immune Marker Profile at 1 Year of Age. Front Immunol 2019;10:2939. [PMID: 31998285 DOI: 10.3389/fimmu.2019.02939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
108 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 119] [Cited by in F6Publishing: 126] [Article Influence: 39.7] [Reference Citation Analysis]
109 Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol 2020;55:579-87. [PMID: 32130521 DOI: 10.1007/s00535-020-01678-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
110 Wang Z, Chen T, Yang C, Bao T, Yang X, He F, Zhang Y, Zhu L, Chen H, Rong S, Yang S. Secoisolariciresinol diglucoside suppresses Dextran sulfate sodium salt-induced colitis through inhibiting NLRP1 inflammasome. International Immunopharmacology 2020;78:105931. [DOI: 10.1016/j.intimp.2019.105931] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
111 Alter DN. Clinical chemistry of the gastrointestinal disorders. Contemporary Practice in Clinical Chemistry 2020. [DOI: 10.1016/b978-0-12-815499-1.00032-6] [Reference Citation Analysis]
112 Fujita Y, Khateb A, Li Y, Tinoco R, Zhang T, Bar-Yoseph H, Tam MA, Chowers Y, Sabo E, Gerassy-Vainberg S, Starosvetsky E, James B, Brown K, Shen-Orr SS, Bradley LM, Tessier PA, Ronai ZA. Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis. Cell Rep 2018;24:3296-3311.e6. [PMID: 30232010 DOI: 10.1016/j.celrep.2018.08.057] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
113 Bourgonje AR, von Martels JZH, Gabriëls RY, Blokzijl T, Buist-Homan M, Heegsma J, Jansen BH, van Dullemen HM, Festen EAM, Ter Steege RWF, Visschedijk MC, Weersma RK, de Vos P, Faber KN, Dijkstra G. A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:251. [PMID: 31772929 DOI: 10.3389/fmed.2019.00251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
114 Eichele DD, Young R. Medical Management of Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1223-35. [PMID: 31676060 DOI: 10.1016/j.suc.2019.08.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
115 Slimming J. LOGROS Y DESAFÍOS DEL TRATAMIENTO DE LA ENFERMEDAD INFLAMATORIA INTESTINAL EN CHILE. Revista Médica Clínica Las Condes 2019;30:344-348. [DOI: 10.1016/j.rmclc.2019.07.005] [Reference Citation Analysis]
116 Bourgonje AR, Gabriëls RY, de Borst MH, Bulthuis MLC, Faber KN, van Goor H, Dijkstra G. Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. Antioxidants (Basel) 2019;8:E351. [PMID: 31480545 DOI: 10.3390/antiox8090351] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
117 Feng BS, Ma N, Zhang YY, Gao H, Zhang C, Li G, Liu Z, Feng Y, Yu HQ, Xiao L, Liu ZG, Yang PC. Survivin Impairs the Apoptotic Machinery in CD4+ T Cells of Patients with Ulcerative Colitis. J Innate Immun 2020;12:226-34. [PMID: 31330513 DOI: 10.1159/000500546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
118 Loktionov A. Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. World J Gastroenterol 2019; 25(27): 3503-3526 [PMID: 31367153 DOI: 10.3748/wjg.v25.i27.3503] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 12.5] [Reference Citation Analysis]
119 Brechmann T, Günther K, Neid M, Tannapfel A, Schmiegel W. Phenotype of histologically suspected drug-induced colitis; results of a comparative, retrospective cohort study. Scand J Gastroenterol 2019;54:855-62. [PMID: 31215277 DOI: 10.1080/00365521.2019.1630674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
121 Chen YL, Zheng YY, Dai YC, Zhang YL, Tang ZP. Systems pharmacology approach reveals protective mechanisms of Jian-Pi Qing-Chang decoction on ulcerative colitis. World J Gastroenterol 2019; 25(21): 2603-2622 [PMID: 31210713 DOI: 10.3748/wjg.v25.i21.2603] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
122 Scaioli E, Belluzzi A, Ricciardiello L, Del Rio D, Rotondo E, Mena P, Derlindati E, Danesi F. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials 2019;20:327. [PMID: 31171016 DOI: 10.1186/s13063-019-3321-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
123 Kramer NE, Cosgrove VE, Dunlap K, Subramaniapillai M, Mcintyre RS, Suppes T. A clinical model for identifying an inflammatory phenotype in mood disorders. Journal of Psychiatric Research 2019;113:148-58. [DOI: 10.1016/j.jpsychires.2019.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
124 Manzoni AG, Passos DF, da Silva JL, Bernardes VM, Bremm JM, Jantsch MH, de Oliveira JS, Mann TR, de Andrade CM, Leal DB. Rutin and curcumin reduce inflammation, triglyceride levels and ADA activity in serum and immune cells in a model of hyperlipidemia. Blood Cells, Molecules, and Diseases 2019;76:13-21. [DOI: 10.1016/j.bcmd.2018.12.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
125 Shishkina TN, Smirnov IE, Kucherenko AG, Kucherov YI, Rekhviashvili MG. Serum calprotectin, C-reactive protein and procalcitonin in preterm infants with necrotizing enterocolitis. jour 2019;19:217-222. [DOI: 10.18821/1560-9561-2016-19-4-217-222] [Reference Citation Analysis]
126 Smirnov IE, Shishkina TN, Kucherenko AG, Kucherov YI. Cytokines and matrix metalloproteinases in premature infants with necrotizing enterocolitis. jour 2019;19:343-350. [DOI: 10.18821/1560-9561-2016-19-6-343-350] [Reference Citation Analysis]
127 Retnakumar SV, Muller S. Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases. Trends Mol Med 2019;25:516-37. [PMID: 30952481 DOI: 10.1016/j.molmed.2019.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
128 Egea Valenzuela J, Ródenas GA, Sánchez Martínez A. Use of biomarkers in inflammatory bowel disease. Medicina Clínica (English Edition) 2019;152:310-316. [DOI: 10.1016/j.medcle.2018.10.018] [Reference Citation Analysis]
129 Catt H, Hughes D, Kirkham JJ, Bodger K. Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. Aliment Pharmacol Ther 2019;49:978-96. [PMID: 30828852 DOI: 10.1111/apt.15174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
130 Gisbert JP, Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. J Crohns Colitis 2019;13:374-84. [PMID: 30307487 DOI: 10.1093/ecco-jcc/jjy158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
131 Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol 2019; 25(10): 1266-1277 [PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
132 Manfredi M, Conte E, Barberis E, Buzzi A, Robotti E, Caneparo V, Cecconi D, Brandi J, Vanni E, Finocchiaro M, Astegiano M, Gariglio M, Marengo E, De Andrea M. Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease. Journal of Proteomics 2019;195:138-49. [DOI: 10.1016/j.jprot.2018.10.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
133 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 612] [Cited by in F6Publishing: 559] [Article Influence: 153.0] [Reference Citation Analysis]
134 Stevens TW, D'Haens GR, Duijvestein M, Bemelman WA, Buskens CJ, Gecse KB. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J 2019;7:496-506. [PMID: 31065367 DOI: 10.1177/2050640619834464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
135 Obraztsov IV, Shirokikh KE, Obraztsova OI, Shapina MV, Wang MH, Khalif IL. Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients. Inflamm Bowel Dis 2019;25:524-31. [PMID: 30544140 DOI: 10.1093/ibd/izy358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
136 Ait-oudhia S, Lien YTK, Basu S, Lesko L, Schmidt S. Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch10] [Reference Citation Analysis]
137 Sahin M, Bobusoglu O, Yetim A, Ates F. Paraoxonase-1 and arylesterase levels in patients with ulcerative colitis. Arab J Gastroenterol 2019;20:14-8. [PMID: 30745012 DOI: 10.1016/j.ajg.2019.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
138 Li P, Lei J, Hu G, Chen X, Liu Z, Yang J. Matrine Mediates Inflammatory Response via Gut Microbiota in TNBS-Induced Murine Colitis. Front Physiol. 2019;10:28. [PMID: 30800071 DOI: 10.3389/fphys.2019.00028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
139 von Martels JZH, Bourgonje AR, Harmsen HJM, Faber KN, Dijkstra G. Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA. PLoS One 2019;14:e0211973. [PMID: 30730969 DOI: 10.1371/journal.pone.0211973] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
140 Fuchs S, Sawas N, Staedler N, Schubert DA, D'Andrea A, Zeiser R, Piali L, Hruz P, Frei AP. High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis. Eur J Immunol 2019;49:462-75. [PMID: 30578679 DOI: 10.1002/eji.201847862] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
141 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
142 Weimers P, Ankersen DV, Munkholm P. Biomarkers for Remote Monitoring. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Fiocchi C. Bringing It Altogether: A Systems Biology Approach to Biomarkers in Inflammatory Bowel Disease. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_30] [Reference Citation Analysis]
144 Segal JP, Hart AL. The Role of Biomarkers in the Ileal Anal Pouch. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_14] [Reference Citation Analysis]
145 Poggioli G, Renzi N. Presentation and Natural Course of Ulcerative Colitis. Ulcerative Colitis 2019. [DOI: 10.1007/978-88-470-3977-3_2] [Reference Citation Analysis]
146 Fernández-tomé S, Montalban-arques A, Díaz-guerra A, Galvan-roman JM, Marin AC, Mora-gutiérrez I, Ortega Moreno L, Santander C, Sánchez B, Chaparro M, Gisbert JP, Bernardo D. Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. Journal of Functional Foods 2019;52:459-68. [DOI: 10.1016/j.jff.2018.11.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
147 Szirmay B, Tárnok A, Sarlós P, Szigeti N, Ludány A, Kustán P, Horváth-Szalai Z, Miseta A, Kőszegi T. Elevated urinary orosomucoid excretion as a novel biomarker in Crohn's disease. Eur J Clin Invest 2019;49:e13054. [PMID: 30451301 DOI: 10.1111/eci.13054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
148 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D'Haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [PMID: 30378142 DOI: 10.1111/apt.15033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
149 Egea Valenzuela J, Antón Ródenas G, Sánchez Martínez A. Use of biomarkers in inflammatory bowel disease. Med Clin (Barc) 2019;152:310-6. [PMID: 30502302 DOI: 10.1016/j.medcli.2018.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
150 Dmochowska N, Tieu W, Keller MD, Wardill HR, Mavrangelos C, Campaniello MA, Takhar P, Hughes PA. Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis. J Nucl Med 2019;60:858-63. [PMID: 30413657 DOI: 10.2967/jnumed.118.219287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
151 Carlsen K, Riis LB, Elsberg H, Maagaard L, Thorkilgaard T, Sørbye SW, Jakobsen C, Wewer V, Florholmen J, Goll R, Munkholm P. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol 2018;53:825-30. [PMID: 29968483 DOI: 10.1080/00365521.2018.1482956] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
152 Takis PG, Taddei A, Pini R, Grifoni S, Tarantini F, Bechi P, Luchinat C. Fingerprinting Acute Digestive Diseases by Untargeted NMR Based Metabolomics. Int J Mol Sci 2018;19:E3288. [PMID: 30360494 DOI: 10.3390/ijms19113288] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
153 Lehmann-werman R, Zick A, Paweletz C, Welch M, Hubert A, Maoz M, Davidy T, Magenheim J, Piyanzin S, Neiman D, Moss J, Golan H, Israeli E, Fischer M, Segal E, Grompe M, Pikarsky A, Golan T, Glaser B, Shemer R, Wolpin B, Dor Y. Specific detection of cell-free DNA derived from intestinal epithelial cells using methylation patterns.. [DOI: 10.1101/409219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
154 Takahashi MK, Tan X, Dy AJ, Braff D, Akana RT, Furuta Y, Donghia N, Ananthakrishnan A, Collins JJ. A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. Nat Commun 2018;9:3347. [PMID: 30131493 DOI: 10.1038/s41467-018-05864-4] [Cited by in Crossref: 150] [Cited by in F6Publishing: 154] [Article Influence: 30.0] [Reference Citation Analysis]
155 Pak S, Hwang SW, Shim IK, Bae SM, Ryu YM, Kim HB, Do EJ, Son HN, Choi EJ, Park SH, Kim SY, Park SH, Ye BD, Yang SK, Kanai N, Maeda M, Okano T, Yang DH, Byeon JS, Myung SJ. Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats. Sci Rep 2018;8:11314. [PMID: 30054522 DOI: 10.1038/s41598-018-29617-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
156 Schönauen K, Le N, von Arnim U, Schulz C, Malfertheiner P, Link A. Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:1547-57. [PMID: 29668922 DOI: 10.1093/ibd/izy046] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
157 Liefferinckx C, Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:1428-39. [PMID: 29788122 DOI: 10.1093/ibd/izy109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
158 Spencer EA, Davis SM, Mack DR, Boyle BM, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz JF, Baker SS, Rosh JR, Baldassano RN, Oliva-Hemker M, Pfefferkorn MD, Otley AR, Heyman MB, Noe JD, Patel AS, Rufo PA, Alison Marquis M, Walters TD, Collins MH, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC; PROTECT Study Group. Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. Inflamm Bowel Dis 2018;24:1335-43. [PMID: 29718391 DOI: 10.1093/ibd/izy009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
159 Padoan A, D’incà R, Scapellato ML, De Bastiani R, Caccaro R, Mescoli C, Moz S, Bozzato D, Zambon C, Lorenzon G, Rugge M, Plebani M, Basso D. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clinical Chemistry and Laboratory Medicine (CCLM) 2018;56:1926-35. [DOI: 10.1515/cclm-2018-0134] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
160 Dai C, Jiang M, Sun MJ, Cao Q. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2018;33:990-7. [PMID: 29427297 DOI: 10.1111/jgh.14121] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
161 Jiang C, Zhu J, Zhou P, Zhu H, Wang W, Jin Q, Li P. Overexpression of FIBCD1 Is Predictive of Poor Prognosis in Gastric Cancer. Am J Clin Pathol 2018;149:474-83. [PMID: 29659669 DOI: 10.1093/ajcp/aqy013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
162 Brookes MJ, Whitehead S, Gaya DR, Hawthorne AB. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol 2018;9:87-91. [PMID: 29588834 DOI: 10.1136/flgastro-2016-100762] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
163 Piotrowicz G, Klufczyńska A, Kowerzanow J, Banaszkiewicz, P, Rydzewska G. Crohn’s disease activity evaluation based on imaging studies and biomarkers. GHOA 2018;9. [DOI: 10.15406/ghoa.2018.09.00292] [Reference Citation Analysis]
164 Grundy L, Brierley SM. Cross-organ sensitization between the colon and bladder: to pee or not to pee? Am J Physiol Gastrointest Liver Physiol 2018;314:G301-8. [PMID: 29146678 DOI: 10.1152/ajpgi.00272.2017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
165 Bourgonje AR, von Martels JZH, de Vos P, Faber KN, Dijkstra G. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines. PLoS One 2018;13:e0193202. [PMID: 29466406 DOI: 10.1371/journal.pone.0193202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
166 Hosomi S, Yamagami H, Itani S, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Fujiwara Y. Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2018;12:87-95. [PMID: 28961693 DOI: 10.1093/ecco-jcc/jjx124] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
167 Ghweil A, Khodeary A, Aziz SP. Diagnostic Value of Fecal Calprotectin and Serum MMP-9 in Diagnosing Disease Activity of Ulcerative Colitis. OJGas 2018;08:234-244. [DOI: 10.4236/ojgas.2018.86026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
168 Di Ruscio M, Vernia F, Ciccone A, Frieri G, Latella G. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin? Inflamm Bowel Dis 2017;24:78-92. [PMID: 29272479 DOI: 10.1093/ibd/izx011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
169 Minar P, Jackson K, Tsai YT, Sucharew H, Rosen MJ, Denson LA. Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease. Inflamm Bowel Dis 2017;24:198-208. [PMID: 29272485 DOI: 10.1093/ibd/izx022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
170 Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med 2018;41:107-18. [PMID: 29115397 DOI: 10.3892/ijmm.2017.3244] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
171 Uchihara M, Kato J, Tsuda S, Yoshida T, Maekita T, Iguchi M, Kitano M. Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis. JGH Open 2017;1:98-104. [PMID: 30483544 DOI: 10.1002/jgh3.12017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
172 Smids C, Horjus Talabur Horje CS, Nierkens S, Drylewicz J, Groenen MJM, Wahab PJ, van Lochem EG. Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course. J Crohns Colitis 2017;11:1090-100. [PMID: 28369318 DOI: 10.1093/ecco-jcc/jjx049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
173 Ma C, Lumb R, Walker EV, Foshaug RR, Dang TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, Fedorak RN, Halloran BP. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study. Inflamm Bowel Dis 2017;23:1643-9. [PMID: 28644184 DOI: 10.1097/MIB.0000000000001173] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
174 Lee HJ, Kim JH, Kim SW, Joo HA, Lee HW, Kim YS, Park SJ, Hong SP, Kim TI, Kim WH, Kim YH, Cheon JH. Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet's Disease. Dig Dis Sci 2017;62:1953-62. [PMID: 28523576 DOI: 10.1007/s10620-017-4606-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
175 Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1240-6. [PMID: 28498159 DOI: 10.1097/MIB.0000000000001136] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
176 Shih I, Wei S, Yen R, Chang C, Ko C, Lin B, Shun C, Liu K, Wong J, Chang Y. PET/MRI for evaluating subclinical inflammation of ulcerative colitis: PET/MRI in Ulcerative Colitis. J Magn Reson Imaging 2018;47:737-45. [DOI: 10.1002/jmri.25795] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
177 Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease. Intest Res 2017;15:311-7. [PMID: 28670227 DOI: 10.5217/ir.2017.15.3.311] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
178 Wu X, Gao H, Sun W, Yu J, Hu H, Xu Q, Chen X. Nepetoidin B, a Natural Product, Inhibits LPS-stimulated Nitric Oxide Production via Modulation of iNOS Mediated by NF-κB/MKP-5 Pathways: Nepetoidin B Inhibits NO Production. Phytother Res 2017;31:1072-7. [DOI: 10.1002/ptr.5828] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
179 Loktionov A, Chhaya V, Bandaletova T, Poullis A. Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus. J Gastroenterol Hepatol 2017;32:992-1002. [PMID: 27787913 DOI: 10.1111/jgh.13627] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
180 Maconi G. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Biomed 2017;88:25-32. [PMID: 28467330 DOI: 10.23750/abm.v88i1.6360] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
181 Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 2017;152:351-361.e5. [PMID: 27720840 DOI: 10.1053/j.gastro.2016.09.046] [Cited by in Crossref: 159] [Cited by in F6Publishing: 166] [Article Influence: 26.5] [Reference Citation Analysis]
182 Kochhar G, Lashner B. Utility of Biomarkers in the Management of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2017;15:105-15. [PMID: 28138859 DOI: 10.1007/s11938-017-0129-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
183 Palone F, Vitali R, Cucchiara S, Mennini M, Armuzzi A, Pugliese D, DʼIncà R, Barberio B, Stronati L. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. Inflamm Bowel Dis 2016;22:2886-93. [PMID: 27755215 DOI: 10.1097/MIB.0000000000000938] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
184 Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho GT, Pattenden RJ, Wilson DC, Satsangi J. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. Am J Gastroenterol 2016;111:1796-805. [PMID: 27596694 DOI: 10.1038/ajg.2016.342] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
185 Boyapati RK, Kalla R, Satsangi J, Ho GT. Biomarkers in Search of Precision Medicine in IBD. Am J Gastroenterol 2016;111:1682-90. [PMID: 27670602 DOI: 10.1038/ajg.2016.441] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
186 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
187 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 1306] [Cited by in F6Publishing: 1116] [Article Influence: 186.6] [Reference Citation Analysis]
188 Ciccia F, Ferrante A, Guggino G, Triolo G. The role of the gastrointestinal tract in the pathogenesis of rheumatic diseases. Best Pract Res Clin Rheumatol 2016;30:889-900. [PMID: 27964794 DOI: 10.1016/j.berh.2016.10.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
189 Hiyama S, Iijima H, Kawai S, Mukai A, Shiraishi E, Iwatani S, Yamaguchi T, Araki M, Hayashi Y, Shinzaki S, Mizushima T, Tsujii M, Takehara T. Narrow-band imaging with magnifying endoscopy for Peyer's patches is useful in predicting the recurrence of remissive patients with ulcerative colitis. Intest Res 2016;14:314-21. [PMID: 27799882 DOI: 10.5217/ir.2016.14.4.314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
190 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol 2016;13:654-64. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 11.0] [Reference Citation Analysis]
191 Iborra M, Beltrán B, Nos P. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2016;26:641-56. [PMID: 27633593 DOI: 10.1016/j.giec.2016.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
192 Heier CR, Fiorillo AA, Chaisson E, Gordish-Dressman H, Hathout Y, Damsker JM, Hoffman EP, Conklin LS. Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. Clin Transl Gastroenterol 2016;7:e192. [PMID: 27628422 DOI: 10.1038/ctg.2016.49] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
193 Jansen I, Prager M, Valentini L, Büning C. Inflammation-driven malnutrition: a new screening tool predicts outcome in Crohn's disease. Br J Nutr 2016;116:1061-7. [PMID: 27546478 DOI: 10.1017/S0007114516003044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
194 Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Ruegger P, Asadourian M, Moon BH, Ayson A, Borneman J, McGovern DP, Fornace AJ Jr, Braun J, Dubinsky M. A Disease-Associated Microbial and Metabolomics State in Relatives of Pediatric Inflammatory Bowel Disease Patients. Cell Mol Gastroenterol Hepatol 2016;2:750-66. [PMID: 28174747 DOI: 10.1016/j.jcmgh.2016.06.004] [Cited by in Crossref: 128] [Cited by in F6Publishing: 123] [Article Influence: 18.3] [Reference Citation Analysis]
195 Bodelier AG, Pierik MJ, Lenaerts K, de Boer E, Olde Damink SW, Hameeteman WM, Masclee AA, Jonkers DM. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2016;28:807-13. [PMID: 26919325 DOI: 10.1097/MEG.0000000000000616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
196 Stidham RW, Cross RK. Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc 2016;18:123-30. [PMID: 28458507 DOI: 10.1016/j.tgie.2016.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
197 Kohler I, Verhoeven A, Derks RJ, Giera M. Analytical pitfalls and challenges in clinical metabolomics. Bioanalysis 2016;8:1509-32. [DOI: 10.4155/bio-2016-0090] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
198 Mitsuhashi S, Feldbrügge L, Csizmadia E, Mitsuhashi M, Robson SC, Moss AC. Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. Inflamm Bowel Dis 2016;22:1587-95. [PMID: 27271497 DOI: 10.1097/MIB.0000000000000840] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
199 Zhang T, Cui B, Li P, He Z, Long C, Wei L, Peng Z, Ji G, Zhang F. Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis. PLoS One 2016;11:e0158227. [PMID: 27347881 DOI: 10.1371/journal.pone.0158227] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
200 Miyoshi J, Chang EB. The gut microbiota and inflammatory bowel diseases. Transl Res 2017;179:38-48. [PMID: 27371886 DOI: 10.1016/j.trsl.2016.06.002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 11.7] [Reference Citation Analysis]
201 Iaculli E, Agostini M, Biancone L, Fiorani C, Di Vizia A, Montagnese F, Sibio S, Manzelli A, Tesauro M, Rufini A, Sica GS. C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn's disease. Cell Death Discov. 2016;2:16032. [PMID: 27551522 DOI: 10.1038/cddiscovery.2016.32] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
202 Schreiber S, Vermeire S. How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases. Gastroenterology 2016;150:1061-6. [PMID: 27018485 DOI: 10.1053/j.gastro.2016.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
203 Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol 2016;9:199-212. [PMID: 26929782 DOI: 10.1177/1756283X15621230] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
204 Huang V, Fedorak R. A 29-year-old woman with Crohn disease considering pregnancy. CMAJ 2016;188:131-2. [PMID: 26438019 DOI: 10.1503/cmaj.150640] [Reference Citation Analysis]
205 Weinberger KM, Breit M. Targeted Metabolomics: The Next Generation of Clinical Chemistry! Translational Bioinformatics 2016. [DOI: 10.1007/978-94-017-7543-4_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Li GH, Guo CQ, Liu QQ. Bowel preparation with polyethylene glycol electrolyte powder lowers serum levels of IL-6 and CRP in patients with mild to moderate active ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2015; 23(35): 5711-5714 [DOI: 10.11569/wcjd.v23.i35.5711] [Reference Citation Analysis]
207 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 96] [Article Influence: 12.0] [Reference Citation Analysis]
208 Carethers JM, Braun J, Sands BE. Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology 2015;149:1131-3. [PMID: 26327133 DOI: 10.1053/j.gastro.2015.08.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
209 Jiang CZ, Yan XZ. Fecal calprotectin for diagnosis of digestive system diseases. Shijie Huaren Xiaohua Zazhi 2015; 23(25): 4069-4074 [DOI: 10.11569/wcjd.v23.i25.4069] [Reference Citation Analysis]